ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC

By zzbiotech | May 24, 2022

3K3A-APC Granted Fast-Track Designation by FDA with Multinational Clinical Trial to Run Through NIH StrokeNet Houston, May 24, 2022, — In a significant development for the treatment of acute ischemic stroke, the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), awarded the first $4 million of…

Read More

ZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

By zzbiotech | December 2, 2021

Houston, TX December 2, 2021 — ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic…

Read More